Across radiation oncology disciplines, from breast cancer to prostate cancer, the last decade has seen a trend toward shorter courses of definitive radiotherapy, termed hypofractionation. The main driver of this trend is the availability of better imaging, planning, and radiotherapy technology, which allows significantly more precise treatment delivery. Thus, the radiation dose delivered to nontarget tissues has declined dramatically, allowing many radiation oncologists to feel comfortable delivering higher daily doses, resulting in shorter treatment courses. Furthermore, the success of stereotactic body radiotherapy has raised the question of whether our understanding of radiation biology has underappreciated the effects of higher doses per fraction on tumor control.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Khandekar MJ, Keane FK. Radiation Dose and Fractionation in Locally Advanced Lung Cancer: A Simple Question With a Complicated Answer. JAMA Oncol. 2021;7(10):1505–1506. doi:10.1001/jamaoncol.2021.3180
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.